Merck, Incyte immunotherapy combination effective in lung cancer study – Nasdaq
Nasdaq |
Merck, Incyte immunotherapy combination effective in lung cancer study
Nasdaq (Adds share move, links to stories on other ASCO research released) By Bill BerkrotMay 17 (Reuters) – A combination of the Merck & Co <MRK.N> immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte … Incyte shares lifted by positive early-stage trial results for cancer drug Aduro Biotech, Merck Team on Cancer Drug Trial Merck says test shows Keytruda improves survival for bladder cancer patients |
